BIOYF (BIOYF) Stock Price & Analysis
BIOYF (BIOYF) fell 1.12% to USD 11.47 as of September 9, 2026 at 00:05 UTC, according to Nexqual real-time market data.
BIOYF last closed at USD 11.6; the session ranged USD 11.45–11.5 on volume of 900 shares. Market capitalization is $129.71M, with a 52-week range of USD 7.63–12 (PNK). Source: Nexqual, September 9, 2026 at 00:05 UTC.
Key Statistics (as of September 9, 2026 at 00:05 UTC)
| Price | USD 11.47 |
|---|---|
| Change | ▼ 1.12% (down) |
| Previous Close | USD 11.6 |
| Open | USD 11.45 |
| Day Range | USD 11.45 – 11.5 |
| 52-Week Range | USD 7.63 – 12 |
| Volume | 900 shares |
| Market Cap | $129.71M |
| Exchange | PNK |
Technical Analysis (BIOYF)
Nexqual's technical model rates BIOYF "STRONG BUY" based on 5 bullish and 0 bearish signals across 126 daily candles, as of September 9, 2026 at 00:05 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.87 (neutral) |
| vs SMA50 | Above (USD 10.69) |
| MACD | 0.25 (positive) |
Analyst Ratings (BIOYF)
Wall Street analysts rate BIOYF "None", per Nexqual as of September 9, 2026 at 00:05 UTC.
| Consensus Rating | None |
|---|
Earnings (BIOYF)
| Next Earnings Date | 2026-11-19 |
|---|---|
| Revenue Estimate | $19.50M |
Source: Nexqual, September 9, 2026 at 00:05 UTC.
Financials & Fundamentals (BIOYF)
| Total Revenue | $55.67M |
|---|---|
| Revenue Growth (YoY) | +95.20% |
| Gross Margin | +73.38% |
| Operating Margin | +20.60% |
| Profit Margin | +17.72% |
| ROE | +23.65% |
| Debt / Equity | 6.85 |
| Current Ratio | 2.07 |
| Total Cash | $8.94M |
| Total Debt | $3.14M |
| Free Cash Flow | $7.59M |
Source: Nexqual, September 9, 2026 at 00:05 UTC.
Financial Health Score (BIOYF)
Nexqual rates BIOYF's overall financial health "Solid" across five dimensions, as of September 9, 2026 at 00:05 UTC.
| Growth | Strong — Revenue +23% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $9M cash vs $3M debt, net cash position |
| Cash Flow | Strong — FCF $8M, 18% margin |
| Efficiency | Strong — ROE 24%, ROA 15.9% |
Ownership (BIOYF)
| Insider Ownership | +34.92% |
|---|---|
| Institutional Ownership | +3.97% |
| Shares Outstanding | 11.31M |
| Float | 9.13M |
Source: Nexqual, September 9, 2026 at 00:05 UTC.
Leadership (BIOYF)
BIOYF is led by René C. Goehrum (age 66), Chairman, CEO & President, per Nexqual as of September 9, 2026 at 00:05 UTC.
| Chairman, CEO & President | René C. Goehrum (age 66) |
|---|---|
| VP of Finance & CFO | Robert J. March |
| Vice President of Corporate Development | Joost van der Mark |
| Director of Human Resources | Neelu Atwal |
Major Backers & Investors (BIOYF)
Notable institutional backers of BIOYF include Grandeur Peak Global Trust-Grandeur Peak Global Contrarian Fund, according to Nexqual as of September 9, 2026 at 00:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Grandeur Peak Global Trust-Grandeur Peak Global Contrarian Fund | 2.26% |
Source: Nexqual, September 9, 2026 at 00:05 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CPHRF | Cipher Pharmaceuticals, Inc. | USD 10.39 | ▼ 0.76% |
| SMTI | Sanara MedTech Inc. | USD 35.05 | ▲ 0.95% |
| PFHO | Pacific Health Care Organizatio | USD 1.05 | ▲ 1.94% |
| WFCF | Where Food Comes From, Inc. | USD 13.17 | ▼ 6.17% |
| LEAT | Leatt Corp. | USD 12.25 | ▲ 1.66% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 00:05 UTC. This page is informational and not investment advice.